“The Wilson Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Wilson Disease pipeline products will significantly revolutionize the Wilson Disease market dynamics”
The Wilson Disease market report provides current treatment practices, Wilson Disease emerging drugs, market share of individual therapies, and current and forecasted 7MM Wilson Disease market size from 2019 to 2032. The report also covers current Wilson Disease treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Wilson Disease Market Research Report
- The increase in Wilson Disease market size is a direct consequence of the increasing patient population of Wilson’s disease in the 7MM.
- Assessments as per DelveInsight’s analysts showed that in 2022, in Germany there was around 916 cases of Wilson’s disease was diagnosed which will increase by 2032.
- The leading companies working in the Wilson Disease Market include Orphalan, AstraZeneca, Vivet Therapeutics, Pfizer, Ultragenyx Pharmaceutical, Aptiv Solutions, Alexion, Ultragenyx Pharmaceutical Inc, Bausch Health Americas Inc., and others.
- Promising Wilson Disease Pipeline Therapies in the various stages of development include TETA 4HCL, VTX-801, UX701, trientine dihydrochloride, ALXN1840, Bis-Choline Tetrathiomolybdate, Trientine, Penicillamine (D1-W12), Penicillamine (W12-W60), and others.
- April 2023: Vivet Therapeutics SAS announced a study of Phase 1 & 2 Clinical Trials for VTX-801. The objectives of this clinical trial are to assess, for up to 5 years, the safety, tolerability and pharmacological activity of a single ascending doses of VTX-801, a gene therapy, administered intravenously (IV) to adult patients with Wilson’s Disease prior to and following background WD therapy withdrawal.
- July 2023: Alexion announced a study of Phase 2 Clinical Trials for Bis-Choline Tetrathiomolybdate. The main objective of the study is to evaluate the change in liver copper (Cu) concentration following 48 weeks of treatment with ALXN1840 in adult participants with Wilson Disease (WD) who have been previously treated for at least 1 year with standard of care (that is, trientine, penicillamine, or zinc). In the Treatment Period, efficacy and safety of ALXN1840 will be assessed at Week 48.
- September 2023: Ultragenyx Pharmaceutical Inc. announced a study of Phase 1 & 2 Clinical Trials for UX701. The primary objectives of this study are to evaluate the safety of single IV doses of UX701 in patients with Wilson disease, to select the UX701 dose with the best benefit/risk profile based on the totality of safety and efficacy data and to evaluate the effect of UX701 on copper regulation.
Discover more about therapies set to grab major Wilson Disease Market Share @ Wilson Disease Market Size
Wilson Disease Overview
Wilson’s disease (WD) is a genetic disorder that prevents the body from removing extra copper, causing copper to build up in the liver, brain, eyes, and other organs. Without treatment, high copper levels can cause life-threatening organ damage.
Wilson Disease Epidemiology Segmentation in the 7MM
- Wilson Disease Prevalent Cases
- Wilson Disease Diagnosed Prevalent Cases based on Clinical Manifestations in the 7MM
- Wilson Disease Diagnosed Prevalent Cases
- Wilson Disease Diagnosed Prevalent cases based on Symptoms
Download the report to understand which factors are driving Wilson Disease Epidemiology Trends @ Wilson Disease Epidemiological Insights
Wilson Disease Market Growth
The disease awareness and emergence of new products in the pipeline will add to the market growth in the future. In addition, persistently rising cases of Wilson’s disease in the forecast period will contribute to the rise in the Wilson’s disease treatment market.
Wilson Disease Market Dynamics
The Wilson’s disease market dynamics are anticipated to change in the coming years owing to the improvement in the research and development undertaking. Despite advancements in treatment, there are a number of unmet needs in treatment management that must be addressed in order to produce successful and safe Wilson’s disease therapies to meet the demands of patients.
To know more about Wilson Disease Treatment options, visit @ Wilson Disease Drugs
Wilson Disease Emerging Drugs
- ALXN1840: Alexion Pharmaceuticals
ALXN1840 (bis-choline tetrathiomolybdate) is a novel oral copper-protein binding agent with a unique mechanism of action, under investigation for Wilson disease, a rare, chronic, genetic, and potentially life-threatening liver disorder of impaired copper transport. Enrollment of participants have been completed in a Phase 3 study of ALXN1840 in Wilson disease. The study results are expected in the first half of 2022.
- TETA 4HCL: Orphalan
Triethylenetatramine (TETA) is a highly selective divalent Cu(II) chelator and a drug that revereses copper overload in tissues. Trientine is a copper chelator used in the treatment of Wilson’s disease as an alternative to D-penicillamine. Clinical trials for TETA 4HCL are being carried out in phase III stage of development for the treatment of Wilsons disease.
Wilson Disease Treatment Market
The main aim of the current treatment is to establish a negative copper balance with the life-long administration of chelating agents (D-penicillamine, trientine salts) or zinc salt. D-penicillamine is available under the brand name Cuprimine and Depen while trientine under Syprine and Trientine Dihydrochloride (Cufence). Treatment helps to improve the manifestations of the disease over time, and its effectiveness depends on strict adherence to it throughout life. Restriction of copper-rich foods may be beneficial. Liver transplantation is the recommended therapy in cases of acute liver failure with encephalopathy or decompensated cirrhosis despite drug therapy.
Learn more about the Wilson Disease Pipeline Therapies in clinical trials @ Wilson Disease Market Landscape
Scope of the Wilson Disease Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Wilson Disease Companies- Orphalan, AstraZeneca (NYSE: AZN), Vivet Therapeutics, Pfizer (NYSE: PFE), Ultragenyx Pharmaceutical (NYSE: RARE), Aptiv Solutions (NYSE: APTV), Alexion (NYSE: ALXN), Bausch Health Americas Inc. (NYSE: BHC), and others.
- Wilson Disease Pipeline Therapies- TETA 4HCL, VTX-801, UX701, trientine dihydrochloride, ALXN1840, Bis-Choline Tetrathiomolybdate, Trientine, Penicillamine (D1-W12), Penicillamine (W12-W60), and others.
- Wilson Disease Market Dynamics: Wilson Disease Market Drivers and Barriers
- Wilson Disease Market Access & Reimbursement, Analyst Views, and Future Perspective
Discover more about Wilson Disease Drugs in development @ Wilson Disease Ongoing Clinical Trials Analysis
Table of Content
- Key Insights
- Wilson Disease Market Report Introduction
- Wilson Disease Market Overview at a Glance
- Wilson Disease Executive Summary
- Wilson Disease Market Disease Background and Overview
- Wilson Disease Patient Journey
- Wilson Disease Epidemiology and Patient Population
- Wilson Disease Marketed Therapies
- Wilson Disease Emerging Therapies
- Wilson’s disease: 7 Major Market Analysis
- Wilson Disease Market Access
- Wilson Disease SWOT Analysis
- Wilson Disease Unmet Needs
- DelveInsight Capabilities
- About DelveInsight
List of Top Trending Market Research Reports in 2023
Soft Tissue Defect Market | Stem Cell Market | Tuberculosis Market | Varicose Vein Treatment Devices Market |Acute Pharyngitis Market | Bartonellosis Market | Concussions Market Size | Allergic Rhinoconjunctivitis Market | Atherectomy Devices Market | Heavy Metal Poisoning Markets | Nipah Virus Infection Market | Central Venous Catheters Market | Acral Lentiginous Melanoma Market | Malt Lymphoma Market | Rhino Conjunctivitis Market | Defibrillators Market | Pulse Oximeters Market | Angioedema Market | Alopecia Aerata Market | Alopecia Areata Market | Bipolar Depression Market | Capnography Device Market | Bone And Joint Infection Market | Brain Aneurysm Stents Market | Hearing Aid Devices Market | Immunologic Deficiency Syndrome Market | Radiation Toxicity Market | Advanced Cancer Pain Management Market | Alport Syndrome Market | Pain Management Devices Market | Polycythemia Market | Vertigo Market | Actinic Keratosis Market | Acute Pulmonary Embolism Market | Ambulatory Arrhythmia Monitoring Devices Market | Aortic Stenosis Market | Chemotherapy Induced Thrombocytopenia Market | Dysthymia Market | Human Papillomavirus Positive Cancer Market | Onycholysis Market | Penicillinbinding Proteins Market | Postsurgical Pain Market | Familial Chylomicronemia Syndrome Market | Geographic Atrophy Market | Group B Streptococcus Market | Herpetic Keratitis Market | Hot Flashes in Prostate Cancer Market | Insomnia Market | Underactive Bladder Market | Cough in Idiopathic Pulmonary Fibrosis Market | Hepatorenal Syndrome Market | Hyperphosphatemia Market | PCSK9 Inhibitors Market | Oral Mucositis Market | Parkinson’s Disease Psychosis Market | Thrombotic Thrombocytopenic Purpura Market | Uncomplicated Urinary Tract Infection Market | Urea Cycle Disorders Market | Venous Thromboembolism Market | Von Hippel-Lindau Disease Market | Soft Tissue Sarcoma with Lung Metastases Market | Synovial Sarcoma Market | Sciatica Market | Sensorineural Hearing Loss Market
Read More about Consulting Services:
Biotech Consulting | Business Consulting Services | Consulting Services | Healthcare Business Development | Healthcare Consulting Services | Healthcare Strategy Consulting | Life Science Consulting | Life Science Consulting Firms
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers & Acquisitions.